|
Name |
7-hydroxy-13-dehydroxypaxilline
|
Molecular Formula | C27H33NO4 | |
IUPAC Name* |
5-hydroxy-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-8-one
|
|
SMILES |
CC(C)(O)C1OC2(O)CCC3(C)C(CCC4Cc5c([nH]c6ccccc56)C43C)C2=CC1=O
|
|
InChI |
InChI=1S/C27H33NO4/c1-24(2,30)23-21(29)14-19-18-10-9-15-13-17-16-7-5-6-8-20(16)28-22(17)26(15,4)25(18,3)11-12-27(19,31)32-23/h5-8,14-15,18,23,28,30-31H,9-13H2,1-4H3/t15-,18-,23-,25-,26+,27-/m0/s1
|
|
InChIKey |
JFVYPWSFDLYZKB-XTHGXZEWSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 435.56 | ALogp: | 4.2 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 82.5 | Aromatic Rings: | 6 |
Heavy Atoms: | 32 | QED Weighted: | 0.604 |
Caco-2 Permeability: | -4.829 | MDCK Permeability: | 0.00001740 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.024 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.015 |
Blood-Brain-Barrier Penetration (BBB): | 0.805 | Plasma Protein Binding (PPB): | 94.60% |
Volume Distribution (VD): | 2.476 | Fu: | 3.02% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.938 |
CYP2C19-inhibitor: | 0.234 | CYP2C19-substrate: | 0.921 |
CYP2C9-inhibitor: | 0.364 | CYP2C9-substrate: | 0.498 |
CYP2D6-inhibitor: | 0.038 | CYP2D6-substrate: | 0.396 |
CYP3A4-inhibitor: | 0.761 | CYP3A4-substrate: | 0.928 |
Clearance (CL): | 8.776 | Half-life (T1/2): | 0.128 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.219 |
Drug-inuced Liver Injury (DILI): | 0.454 | AMES Toxicity: | 0.893 |
Rat Oral Acute Toxicity: | 0.932 | Maximum Recommended Daily Dose: | 0.443 |
Skin Sensitization: | 0.111 | Carcinogencity: | 0.481 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.02 |
Respiratory Toxicity: | 0.981 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005988 | 0.828 | D0H4JM | 0.281 | ||||
ENC002279 | 0.725 | D0U7GP | 0.281 | ||||
ENC000836 | 0.712 | D01JGV | 0.281 | ||||
ENC005989 | 0.615 | D05MQK | 0.263 | ||||
ENC003172 | 0.615 | D0V4WD | 0.262 | ||||
ENC003876 | 0.613 | D04GJN | 0.256 | ||||
ENC002951 | 0.611 | D0Q6NZ | 0.250 | ||||
ENC001492 | 0.603 | D0K0KH | 0.250 | ||||
ENC005406 | 0.600 | D0U3GL | 0.250 | ||||
ENC005405 | 0.573 | D06AEO | 0.250 |